Dr. John Bilello has over 25 years of experience in the pharmaceutical industry, the biotechnology sector, and academic and government laboratories. He was an Associate Professor at the University of Maryland School of Medicine and Albany Medical College. Dr. Bilello joined GlaxoSmithKline (GSK), where he was the Director of Technology Development in Translational Medicine and Genetics. John assessed external technologies in his technology development role, identifying new investment opportunities for GSK’s Technology Investment Board. His work with GSK’s Human Biomarker Laboratories led to tools for stratifying patients and monitoring efficacy in clinical studies. Specifically, he developed biomarkers for enabling studies of new therapeutics for COPD, diabetes/metabolic syndrome, migraine, and neurodegenerative diseases. Before joining GSK, he was a biochemist at Roche Pharmaceuticals, a Volkswagen Fellow at the University of Hamburg (Germany), and the Director of Preclinical Research and Development at two successful biotechnology companies (SRA Lifesciences and Virco Laboratories). As an enthusiastic entrepreneur, John was a founder and Chief Scientific Officer of Ridge Diagnostics, which developed and commercialized a diagnostic for major depressive disorder. At Ridge, he was an inventor on multiple US and international patents and processes. John has authored over seventy publications in refereed journals and more than ten book chapters. An internationally recognized scientist, he was a member of the editorial board for *Antimicrobial Agents and Chemotherapy* (1995-2009). In addition to an established track record of innovative basic and clinical research, Dr. Bilello has extensive experience in project and organizational management. John was a co-founder and Managing Partner of Innovalyst LLC, a small business accelerator focused on catalyzing product innovation in the Life Sciences.

John Bilello Ph.D.

Principal and Consultant at Innovalyst ICAN

About

Publications

(132) Use of a depression biomarker panel to diagnose depression in chronic pain patients

The Journal of Pain

2015

MDDScore

The Journal of Clinical Psychiatry

2015

MDDScore and Biomarker Profiling in Patients Treated with Transcranial Magnetic Stimulation: Preliminary Data

Brain Stimulation

2014

The diagnosis of depression: current and emerging methods

Comprehensive Psychiatry

2013

Development of novel approaches to the evaluation of virucidal agents: separation of treated virions from test compounds

AIDS

2001

The Triple Combination Indinavir-Zidovudine-Lamivudine Is Highly Synergistic

Antimicrobial Agents and Chemotherapy

2000

A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)

AIDS

1996

Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid Glycoprotein

Journal of Infectious Diseases

1995

In vitro pharmacodynamic modeling of anti-retroviral agents and interferon

Antiviral Research

1991

Lymphocyte transformation abnormalities in bovine immunodeficiency-like virus infected calves

Immunology Letters

1991

Altered cellular functions in a PC-12 cell clone chronically infected with retrovirus

Biochemical and Biophysical Research Communications

1986

Interferon-induced alterations in membrane functions and the growth of Daudi lymphoma and Friend leukemia cells

Bioscience Reports

1982

Biosynthesis, Modification and Processing of Viral Polyproteins

Protein Biosynthesis in Eukaryotes

1982

ALTERATIONS IN THE PROCESSING AND SHEDDING OF RETROVIRUS PROTEINS IN FRIEND ERYTHROLEUKEMIA CELLS

Biosynthesis, Modification, and Processing of Cellular and Viral Polyproteins

1980

SFFV SPECIFIC GENE EXPRESSION IN INFECTED AND ERYTHROLEUKEMIA CELLS

Animal Virus Genetics

1980

Growth of Murine Sarcoma Virus-Transformed Rat Kidney Cells in Nude Mice: Absence of Induction of Host Endogenous Viruses 2

JNCI: Journal of the National Cancer Institute

1977

Patterns of chronic inflammation in extensively treated patients with arachnoiditis and chronic intractable pain

Postgraduate Medicine

2016

Seeking an objective diagnosis of depression

Biomarkers in Medicine

2016

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

Molecular Psychiatry

2015

Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study

Molecular Psychiatry

2011

Matrix metalloproteinases during and outside of migraine attacks without aura

Cephalalgia

2009

Profiling serum biomarkers in patients with COPD: associations with clinical parameters

Thorax

2007

Use of Proteomic Patterns of Serum Biomarkers in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Clinical Parameters

Proceedings of the American Thoracic Society

2006

The Agony and Ecstasy of “OMIC” Technologies in Drug Development

Current Molecular Medicine

2005

In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours

Antimicrobial Agents and Chemotherapy

2003

Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System

Antimicrobial Agents and Chemotherapy

2002

Hollow‐Fiber Unit Evaluation of a New Human Immunodeficiency Virus Type 1 Protease Inhibitor, BMS‐232632, for Determination of the Linked Pharmacodynamic Variable

The Journal of Infectious Diseases

2001

Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir

Antimicrobial Agents and Chemotherapy

2000

The Safety and Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor (Sargramostim) Added to Indinavir‐ or Ritonavir‐Based Antiretroviral Therapy: A Randomized Double‐Blind, Placebo‐Controlled Trial

The Journal of Infectious Diseases

1999

Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro

Antimicrobial Agents and Chemotherapy

1998

Phenotypic Variability of Lymphocyte Populations in Peripheral Blood and Lymph Nodes from HIV-Infected Individuals and the Impact of Antiretroviral Therapy

AIDS Research and Human Retroviruses

1998

Factors Influencing the Emergence of Resistance to Indinavir: Role of Virologic, Immunologic, and Pharmacologic Variables

Journal of Infectious Diseases

1998

Predicting Clinical Progression or Death in Subjects with Early‐Stage Human Immunodeficiency Virus (HIV) Infection: A Comparative Analysis of Quantification of HIV RNA, Soluble Tumor Necrosis Factor Type II Receptors, Neopterin, and $\beta _{2}$ -Microglobulin

The Journal of Infectious Diseases

1997

Soluble Tumor Necrosis Factor- Receptor Type II (sTNF RII) Correlates with Human Immunodeficiency Virus (HIV) RNA Copy Number in HIV-Infected Patients

Journal of Infectious Diseases

1996

Antiretroviral Monotherapy in Early Stage Human Immunodeficiency Virus Disease Has No Detectable Effect on Virus Load in Peripheral Blood and Lymph Nodes

Journal of Infectious Diseases

1996

Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation

Antimicrobial Agents and Chemotherapy

1996

Relevance of Plasma Protein Binding to Antiviral Activity and Clinical Efficacy of Inhibitors of Human Immunodeficiency Virus Protease

Journal of Infectious Diseases

1996

Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease

Antimicrobial Agents and Chemotherapy

1996

Transmission in NFS/N mice of the heritable spongiform encephalopathy associated with the gray tremor mutation.

Proceedings of the National Academy of Sciences

1987

Murine Sarcoma Virus Gene Expression: Transformants Which Express Viral Envelope Glycoprotein In The Absence Of The Major Internal Protein And Infectious Particles

Proceedings of the National Academy of Sciences

1974

Education

Albert Einstein College of Medicine

Ph.D/Molecular Biology, Molecular Biology / June, 1977

New York

Southern Illinois University Carbondale

MA/Microbiology, Microbiology / June, 1969

Carbondale, Illinois, United States of America

City College of New York

BS, Biology / January, 1966

New York, New York, United States of America

Albert Einstein College of Medicine

Ph.D/Molecular Biology, Molecular Biology / June, 1977

New York

Southern Illinois University Carbondale

MA/Microbiology, Microbiology / June, 1969

Carbondale, Illinois, United States of America

City College of New York

BS, Biology / January, 1966

New York, New York, United States of America

Experience

Innovalyst ICAN

Principal / July, 2018 — Present

Atlantic Diagnostic Laboratory

Scientific Officer / January, 2017 — Present

Ridge Diagnostic Laboratories

President and Chief Scientific Officer / January, 2009 — December, 2016

Ridge Diagnostics

Founder/Chief Scientific Officer / January, 2006 — December, 2008

GlaxoSmithKline

Director Technology Development / October, 2002 — December, 2005

Senior Therapeutic Area Advisor for Antivirals / January, 2002 — October, 2002

Director Technology Development / October, 2002 — December, 2005

Senior Therapeutic Area Advisor for Antivirals / January, 2002 — October, 2002

Virco Lab

Director, Preclinical Research and Development / June, 2000 — June, 2002

SRA Life Sciences

1998 — 2000

Albany Medical College

Associate Professor of Medicine / 1992 — 1998

Baltimore VA Medical Center

Chief, Molecular Biology Laboratory / 1985 — 1992

University of Maryland Baltimore

Assistant Professor / 1983 — 1989

Johns Hopkins Medicine

Instructor / 1981 — 1983

Join John on NotedSource!

Join Now

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.